KCM
RETA

Kennedy Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Kennedy Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-45,626
Closed -$1.73M – 652
2022
Q4 		$1.73M Sell
45,626
-27,424
-38% -$944K 0.05% 428
2022
Q3 		$1.84M Sell
73,050
-5,631
-7% -$156K 0.05% 428
2022
Q2 		$2.39M Sell
78,681
-898
-1% -$26.8K 0.07% 398
2022
Q1 		$2.61M Buy
79,579
+55
+0.1% +$1.63K 0.06% 412
2021
Q4 		$2.1M Buy
79,524
+9,117
+13% +$705K 0.04% 449
2021
Q3 		$7.08M Sell
70,407
-883
-1% -$104K 0.16% 243
2021
Q2 		$10.1M Sell
71,290
-3,339
-4% -$377K 0.22% 160
2021
Q1 		$7.44M Buy
74,629
+2,625
+4% +$306K 0.15% 255
2020
Q4 		$8.9M Sell
72,004
-788
-1% -$104K 0.2% 169
2020
Q3 		$7.09M Sell
72,792
-656
-0.9% -$82K 0.2% 167
2020
Q2 		$11.5M Sell
73,448
-1,053
-1% -$160K 0.33% 66
2020
Q1 		$10.8M Sell
74,501
-1,431
-2% -$276K 0.4% 35
2019
Q4 		$15.5M Sell
75,932
-89,382
-54% -$16.3M 0.38% 39
2019
Q3 		$13.3M Sell
165,314
-25,895
-14% -$2.2M 0.33% 59
2019
Q2 		$18M Sell
191,209
-4,547
-2% -$393K 0.43% 27
2019
Q1 		$16.7M Sell
195,756
-17,759
-8% -$1.47M 0.39% 37
2018
Q4 		$12M Sell
213,515
-61,257
-22% -$3.74M 0.3% 72
2018
Q3 		$22.5M Sell
274,772
-48,029
-15% -$3.38M 0.42% 33
2018
Q2 		$11.3M Buy
322,801
+84,491
+35% +$2.57M 0.21% 134
2018
Q1 		$4.89M Sell
238,310
-11,496
-5% -$296K 0.1% 406
2017
Q4 		$7.08M Buy
249,806
+45,546
+22% +$1.27M 0.13% 283
2017
Q3 		$6.35M Buy
+204,260
New +$6.14M 0.11% 315

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's RETA Position: Q1 2023 in Review

Kennedy Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 45,626 shares — an estimated $1.73M sold.

Kennedy Capital Management first reported a position in RETA in Q3 2017 and held it in 22 quarters. The position peaked at $22.5M in Q3 2018. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

  • Kennedy Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 45,626 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $1.73M.
  • Kennedy Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 22 quarters.
  • Kennedy Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $22.5M in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Kennedy Capital Management's 13F filing for Q1 2023, filed 15 May 2023.